A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B

NCT07135349 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

209

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: BW-20507 with/without NUC
DRUG: BW-20507 with/without NUC, Peg-IFNa

Sponsor

Shanghai Argo Biopharmaceutical Co., Ltd.